(0.03%) 5 208.25 points
(0.04%) 39 011 points
(-0.04%) 18 188 points
(0.14%) $78.59
(-1.28%) $2.17
(-0.12%) $2 328.40
(-0.50%) $27.48
(0.55%) $970.20
(0.14%) $0.930
(0.33%) $10.86
(0.18%) $0.797
(0.04%) $91.38
2 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 10.31%
-3.01% $ 1.290
Live Chart Being Loaded With Signals
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States...
Stats | |
---|---|
Volumen de hoy | 703 390 |
Volumen promedio | 1.59M |
Capitalización de mercado | 74.50M |
EPS | $0 ( 2024-03-28 ) |
Próxima fecha de ganancias | ( $-0.210 ) 2024-05-09 |
Last Dividend | $0.420 ( 2010-12-09 ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.960 |
ATR14 | $0.00500 (0.39%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-22 | Stergiou Angelos M. | Buy | 159 000 | Common Stock |
2024-01-22 | Stergiou Angelos M. | Buy | 238 500 | Stock Option (Right to Buy) |
2024-01-22 | Scheinberg David A | Buy | 6 000 | Common Stock |
2024-01-22 | Scheinberg David A | Buy | 10 000 | Stock Option (Right to Buy) |
2024-01-22 | Wood Barbara A | Buy | 35 000 | Common Stock |
INSIDER POWER |
---|
95.64 |
Last 98 transactions |
Buy: 3 194 450 | Sell: 76 679 |
Volumen Correlación
Sellas Life Sciences Correlación
10 Correlaciones Más Positivas | |
---|---|
GOODM | 0.893 |
SINO | 0.882 |
RMRM | 0.84 |
XOG | 0.835 |
ENER | 0.835 |
ICON | 0.826 |
IINN | 0.813 |
SSIC | 0.812 |
PMBC | 0.808 |
BWMX | 0.808 |
10 Correlaciones Más Negativas | |
---|---|
CVRX | -0.88 |
SFST | -0.878 |
FXNC | -0.876 |
PDCO | -0.874 |
AIRS | -0.868 |
BDSX | -0.866 |
COMM | -0.852 |
TBNK | -0.849 |
UTME | -0.848 |
REKR | -0.843 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Sellas Life Sciences Correlación - Moneda/Commodity
Sellas Life Sciences Finanzas
Annual | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $0 (0.00 %) |
EPS: | $-1.340 |
FY | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $0 (0.00 %) |
EPS: | $-1.340 |
FY | 2022 |
Ingresos: | $1.00M |
Beneficio Bruto: | $900 000 (90.00 %) |
EPS: | $-2.10 |
FY | 2021 |
Ingresos: | $0.00 |
Beneficio Bruto: | $-200 000 (0.00 %) |
EPS: | $-2.60 |
Financial Reports:
No articles found.
Sellas Life Sciences Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.150 | 2010-09-09 |
Last Dividend | $0.420 | 2010-12-09 |
Next Dividend | $0 | N/A |
Payout Date | 2010-12-20 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $0.570 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.52 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2010 | $0.570 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Royal | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | -5.80 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -23.94 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0.231 | 0.800 | -3.85 | -3.08 | [1 - 3] |
quickRatioTTM | 0.191 | 0.800 | -3.58 | -2.86 | [0.8 - 2.5] |
cashRatioTTM | 0.191 | 1.500 | -0.0473 | -0.0710 | [0.2 - 2] |
debtRatioTTM | 0.141 | -1.500 | 7.64 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 154.42 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.978 | 2.00 | -0.326 | -0.652 | [0 - 30] |
freeCashFlowPerShareTTM | -1.242 | 2.00 | -0.621 | -1.242 | [0 - 20] |
debtEquityRatioTTM | -0.114 | -1.500 | -0.454 | 0.682 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -34.67 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | -2.91 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -1.150 | 1.000 | -0.217 | 0 | [1 - 100] |
returnOnEquityTTM | -23.94 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.242 | 2.00 | -0.414 | -1.242 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.978 | 2.00 | -0.326 | -0.652 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0223 | 1.500 | -3.48 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -1.942 |
Sellas Life Sciences
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico